OPKO Health (OPK Quick QuoteOPK - Free Report) reported $156.8 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 13.9%. EPS of -$0.19 for the same period compares to -$0.01 a year ago.

The reported revenue represents a surprise of -5.09% over the Zacks Consensus Estimate of $165.22 million. With the consensus EPS estimate being -$0.12, the EPS surprise was -58.33%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how OPKO Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Revenue from transfer of intellectual property and other: $15 million versus the five-analyst average estimate of $20.07 million. The reported number represents a year-over-year change of +22%.
• Revenues- Revenue from products: $40.7 million versus $40.88 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.5% change.
• Revenues- Revenue from services: $101.1 million versus $104.29 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -21.9% change.

View all Key Company Metrics for OPKO Health here>>>

Shares of OPKO Health have remained unchanged over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.